Cision PR Newswire.

The entire Volume 8 (2017) is now in PubMed.
Volume 9 (2018) issues (1-88) are now in PubMed. Please see the link.

According to the statement from the MEDLINE reviewers on 6/22/2017,
"This journal continues to play a major role in the publication of important basic science research papers. Editorial practices are consistently high. Ethical guidelines are consistently followed. This is an important research journal for the field."

Oncotarget will continue to be indexed in PMC and PubMed.

Impact factor (IF) Web of Science (Clarivate Analytics)

Year IF Total Cites
2016 5.168 30241
2015 5.008 10452
2014 6.359 3908
2013 6.627 2217
2012 6.636 1450
2011 4.784 493

Scopus/SJR ranking: 2011-ongoing: Q1 (highest rank). All years Q1 in Medicine and Oncology (subject area).

Oncotarget ranks number 1 on Total Documents (2015-2017) among all journals in Oncology, see here

News: Scopus released 2017 ratings. Oncotarget is Q1 (highest rank). It ranks 1 in total documents, with cites per doc (IF equivalent) 4.67

Members of Editorial Board Carlo M. Croce (former Editor-in-Chief of Cancer Research) and Andrew Schally (Nobel Prize winner) have respectively published 27 and 10 papers in Oncotarget.

300 Plus Papers from the Editorial Board:
See full list

Copyright © 2018 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC